CFTR and cystic fibrosis: While there have been other studies examining the composition of the microbiota in the presence of NTMs, with most suggesting a unique bacterial community residing within each pwCF (35, –, 37) or the impact of CFTR modulator therapies on NTM prevalence (38), there has been no research combining NTM complexes, CFTR modulator therapies, and CF-associated lung microbiome.